Ilika plc grants options under the Long Term Incentive Plan

Ilika

Ilika Plc (LON:IKA), a pioneer in solid-state battery technology, has announced that on 28 February 2023 it granted options to Executive Directors and employees under the Long Term Incentive Plan approved by shareholders in 2018 and the EMI scheme.

LTIP

Ilika awarded nominal value options under the LTIP over 416,954 ordinary shares of 1p each in the Company to an Executive Director and options over a further 2,800 Ordinary Shares to employees. Each award vests on the achievement of certain performance targets over a three-year period. 

EMI option scheme

Ilika plc granted market value options over 802,248 ordinary shares of 1p each in the Company to an Executive Director and employees under the Company EMI option scheme.  EMI options vest on the achievement of certain performance targets over a three-year period. 

The awards are intended to align the incentives of the Executive Directors and other senior employees with the Company’s performance and outcomes for shareholders over the long term and to provide effective and attractive levels of reward, based on delivering strong performance in a fair and proportionate manner.

In total, options over 1,222,002 Ordinary Shares have been granted representing 0.77% of issued share capital.

Details of grants issued under the LTIP and EMI option scheme by each Executive Director are set out in the table below, together with the total number of Ordinary Shares each Executive Director holds under option and is interested in.

DirectorNumber of options grantedScheme under which options grantedTotal number of Options now heldPer cent. of issued share capital
Graeme Purdy416,954LTIP2,779,0671.76
Jason Stewart300,000EMI300,0000.19

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Ilika moves into commercial phase with first Stereax electrode order

Ilika has received its first commercial order for Stereax battery electrodes, marking the start of scaled production for medical device applications.

Ilika plc: First Commercial Revenues Signal Pivotal Shift in Solid-State Battery Journey (Video)

Ilika plc has crossed a commercial milestone with its first regular revenue stream from its Stereax battery line, according to Dr Tom McColm of Morphose Capital. With strong cash reserves, momentum on its Goliath platform, and growing interest from defence sectors, the next 12 months could be transformational.

Ilika Plc: Solid-State Breakthroughs Put Stereax and Goliath in the Spotlight (Video)

Ilika CEO Graeme Purdy shares how the company has shifted from commissioning to customer deliveries of its Stereax batteries — and why its Goliath EV programme is designed to beat the commoditised market with faster charging and extended range.

Ilika reports on-track progress across Stereax and Goliath in H1 2025/26

Ilika reports unaudited half-year results to 31 October 2025, highlighting on-schedule delivery of key commercial milestones across its Stereax medical battery and Goliath EV battery programmes, alongside continued customer validation, pilot-line commissioning, and £4.2m fundraising to support its roadmap.

Ilika secures first commercial Stereax electrode order from Cirtec Medical

Ilika has received its first revenue-generating purchase order from Cirtec Medical for the supply of Stereax electrodes, marking the transition of their partnership into commercial production.

Solid state design drives weight, cost and efficiency gains

Solid state design offers Ilika a compelling path to value through weight savings, pack simplification and improved EV performance.

Search

Search